Last reviewed · How we verify
NCT06058234
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
trial testing Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease in Mild Alzheimer's Disease in 8,680 participants. Currently enrolling.
30 June 2028
Quick facts
| Lead sponsor | Centers for Medicare and Medicaid Services/ Coverage and Analysis Group |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 8,680 |
| Start date | 6 July 2023 |
| Primary completion | 30 June 2028 |
| Estimated completion | 30 June 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease — full drug profile →
Conditions studied
- Mild Alzheimer's Disease — all drugs for Mild Alzheimer's Disease →
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease — all drugs for Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease →
Sponsor
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group — full company profile →
Who can join
Eligibility, any sex, with Mild Alzheimer's Disease or Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06058234
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Alzheimer's Disease
Currently open trials in the same condition.
- NCT05417555 — Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06058234 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
- Last refreshed: 28 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06058234.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing